Related Experiment Videos
Resistance to HIV-1 entry inhibitors
1Progenics Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA. olson@progenics.com
Current Drug Targets. Infectious Disorders
|February 3, 2004
Summary
Resistance testing is crucial for managing human immunodeficiency virus type 1 (HIV-1) infection. New HIV-1 entry inhibitors, including attachment, coreceptor, and fusion inhibitors, offer distinct resistance profiles and complementary therapies.
Area of Science:
- Virology
- Infectious Diseases
- Pharmacology
Background:
- Resistance testing is standard for HIV-1 protease and reverse transcriptase inhibitors.
- HIV-1 entry inhibitors represent an emerging class of antiretroviral therapy.
- Understanding viral resistance is key for developing new HIV-1 treatments.
Purpose of the Study:
- To review the role of resistance testing in the context of emerging HIV-1 entry inhibitors.
- To discuss the distinct resistance profiles of attachment, coreceptor, and fusion inhibitors.
- To highlight the complementary nature of these novel therapeutic classes.
Main Methods:
- Review of current clinical trial data for HIV-1 entry inhibitors.
- Analysis of resistance determinants and evolution for distinct inhibitor classes.
- Examination of parallel advances in resistance-testing technologies.
Main Results:
- HIV-1 entry inhibitors encompass attachment, coreceptor, and fusion inhibitors.
- Each class has shown promise in clinical trials.
- Attachment, coreceptor, and fusion inhibitors exhibit distinct resistance profiles.
Conclusions:
- Resistance testing is vital for the optimal deployment of new HIV-1 entry inhibitor therapies.
- These inhibitors offer complementary therapeutic options.
- Distinct resistance profiles necessitate tailored treatment strategies.